The Claim
In patients with coronary artery disease, intensified lipid-lowering therapy using ezetimibe, bempedoic acid, or PCSK-9 inhibitors in addition to statins significantly reduces the risk of ischemic stroke by 23%, with a greater relative risk reduction compared to myocardial infarction, suggesting a potentially enhanced protective effect against cerebrovascular events.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For people with heart disease, adding certain cholesterol-lowering drugs to their usual statin medicine cuts the chance of having a stroke by 23%—and this protection might be even better than for heart attacks.
See the scientific wording
Intensified lipid-lowering therapy with ezetimibe, bempedoic acid, or PCSK-9 inhibitors in addition to statins significantly reduces the risk of ischemic stroke by 23%, more than the reduction seen for myocardial infarction, suggesting a potentially greater protective effect against cerebrovascular events in patients with coronary artery disease.
What the research says
1 studyStudy: Efficacy of lipid lowering therapy beyond statins to prevent cardiovascular events
The study looked at adding drugs like ezetimibe or PCSK-9 inhibitors to statins and found they reduced stroke risk more than heart attack risk, just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.